← Back to Search

Antiretroviral

Open label for HIV

Phase 4
Waitlist Available
Research Sponsored by Southampton Healthcare, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights

Study Summary

This trial looks at whether it's safe to switch HIV medication for people who are already taking elvitegravir/tenofovir alafenamide/emtricitabine/cobicistat and darunavir, and who have a I84 V/I mutation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184
Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184 V/I resistance mutation.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open labelExperimental Treatment1 Intervention
Open label Biktarvy to establish suppression of HIV 1 with 184 V/I Resistance Mutation

Find a Location

Who is running the clinical trial?

Southampton Healthcare, Inc.Lead Sponsor

Frequently Asked Questions

~2 spots leftby May 2025